In:
British Journal of Haematology, Wiley, Vol. 171, No. 4 ( 2015-11), p. 539-546
Abstract:
Bortezomib‐containing combinations are active in non‐Hodgkin lymphoma ( NHL ) although peripheral neuropathy can limit their dose intensity. Based on our phase I findings, we conducted a phase II trial of bortezomib in combination with R‐ CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) with a modified dose of vincristine. Patients with untreated indolent NHL received bortezomib (1·6 mg/m 2 ) on days 1 and 8 of a 21‐day cycle for up to 8 cycles and R‐ CHOP with a 1·5 mg cap of vincristine. Patients achieving a complete response ( CR ) received maintenance rituximab, and remaining patients received maintenance rituximab and bortezomib. The primary endpoint was CR rate; secondary survival analyses were evaluated using the Kaplan–Meier method. Among 29 eligible patients, NHL morphologies included follicular ( n = 20), marginal zone ( n = 5) and small lymphocytic lymphoma ( n = 4). Nineteen patients had CR (66%) and 10 had partial response (34%), yielding a 100% overall response rate. With a median follow‐up of 48·7 months, the 4‐year progression‐free and overall survivals were 83% and 93%. Twenty‐two patients experienced peripheral neuropathy of any grade, and two had grade 3 neuropathy. The combination of bortezomib with R‐ CHOP is effective for indolent NHL , and we plan to evaluate therapies incorporating novel proteasome inhibitors in future studies in NHL .
Type of Medium:
Online Resource
ISSN:
0007-1048
,
1365-2141
DOI:
10.1111/bjh.2015.171.issue-4
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
1475751-5